Nephrotic syndrome after infliximab treatment in a patient with ulcerative colitis

J Gastrointestin Liver Dis. 2015 Jun;24(2):249-51. doi: 10.15403/jgld.2014.1121.242.infx.

Abstract

Tumor necrosis factor (TNF)-targeted therapies are increasingly used to treat a variety of inflammatory and autoimmune diseases. They are now used worldwide, and this class of medication has revolutionized the treatment of these diseases and the quality of life for patients but it also poses risk of developing various side effects including infections, exacerbation of some neurological manifestations, cutaneous lesions or induces antibody production. Renal complications are uncommon and poorly recognized. This report describes a probable case of infliximab-induced focal segmental glomerulosclerosis clinically presented as a severe nephrotic syndrome in a patient with ulcerative colitis.

Publication types

  • Case Reports

MeSH terms

  • Anti-Inflammatory Agents / adverse effects*
  • Colitis, Ulcerative / diagnosis
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / immunology
  • Drug Substitution
  • Gastrointestinal Agents / adverse effects*
  • Glomerulosclerosis, Focal Segmental / chemically induced*
  • Glomerulosclerosis, Focal Segmental / diagnosis
  • Glomerulosclerosis, Focal Segmental / therapy
  • Humans
  • Infliximab / adverse effects*
  • Male
  • Middle Aged
  • Nephrotic Syndrome / chemically induced*
  • Nephrotic Syndrome / diagnosis
  • Nephrotic Syndrome / therapy
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Anti-Inflammatory Agents
  • Gastrointestinal Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab